vs
Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $88.2M, roughly 1.1× FIRST MID BANCSHARES, INC.). FIRST MID BANCSHARES, INC. runs the higher net margin — 26.8% vs 25.0%, a 1.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 5.0%).
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
FMBH vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $88.2M | $92.9M |
| Net Profit | $23.7M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 34.0% | 24.1% |
| Net Margin | 26.8% | 25.0% |
| Revenue YoY | 3.4% | 23.3% |
| Net Profit YoY | 23.5% | 17.3% |
| EPS (diluted) | $0.98 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.2M | $92.9M | ||
| Q3 25 | $89.3M | $67.5M | ||
| Q2 25 | $87.5M | $63.2M | ||
| Q1 25 | $84.3M | $52.6M | ||
| Q4 24 | $85.3M | $75.4M | ||
| Q3 24 | $80.6M | $57.9M | ||
| Q2 24 | $79.2M | $52.7M | ||
| Q1 24 | $79.9M | $51.3M |
| Q4 25 | $23.7M | $23.2M | ||
| Q3 25 | $22.5M | $5.1M | ||
| Q2 25 | $23.4M | $-553.0K | ||
| Q1 25 | $22.2M | $-11.2M | ||
| Q4 24 | $19.2M | $19.8M | ||
| Q3 24 | $19.5M | $-901.0K | ||
| Q2 24 | $19.7M | $-4.7M | ||
| Q1 24 | $20.5M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 34.0% | 24.1% | ||
| Q3 25 | 32.2% | 5.1% | ||
| Q2 25 | 34.4% | -3.2% | ||
| Q1 25 | 33.4% | -24.3% | ||
| Q4 24 | 29.7% | 24.5% | ||
| Q3 24 | 31.5% | -4.3% | ||
| Q2 24 | 33.7% | -11.5% | ||
| Q1 24 | 33.7% | -10.7% |
| Q4 25 | 26.8% | 25.0% | ||
| Q3 25 | 25.2% | 7.5% | ||
| Q2 25 | 26.8% | -0.9% | ||
| Q1 25 | 26.3% | -21.4% | ||
| Q4 24 | 22.5% | 26.3% | ||
| Q3 24 | 24.2% | -1.6% | ||
| Q2 24 | 24.9% | -8.9% | ||
| Q1 24 | 25.6% | -7.5% |
| Q4 25 | $0.98 | $0.46 | ||
| Q3 25 | $0.94 | $0.10 | ||
| Q2 25 | $0.98 | $-0.01 | ||
| Q1 25 | $0.93 | $-0.23 | ||
| Q4 24 | $0.81 | $0.40 | ||
| Q3 24 | $0.81 | $-0.02 | ||
| Q2 24 | $0.82 | $-0.10 | ||
| Q1 24 | $0.86 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $354.5M | — |
| Stockholders' EquityBook value | $958.7M | $354.6M |
| Total Assets | $8.0B | $488.0M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $958.7M | $354.6M | ||
| Q3 25 | $932.2M | $321.9M | ||
| Q2 25 | $894.1M | $306.8M | ||
| Q1 25 | $870.9M | $295.5M | ||
| Q4 24 | $846.4M | $292.0M | ||
| Q3 24 | $858.5M | $257.5M | ||
| Q2 24 | $813.6M | $243.0M | ||
| Q1 24 | $798.0M | $233.9M |
| Q4 25 | $8.0B | $488.0M | ||
| Q3 25 | $7.8B | $453.3M | ||
| Q2 25 | $7.7B | $435.6M | ||
| Q1 25 | $7.6B | $424.6M | ||
| Q4 24 | $7.5B | $432.7M | ||
| Q3 24 | $7.6B | $390.4M | ||
| Q2 24 | $7.6B | $376.8M | ||
| Q1 24 | $7.7B | $356.7M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.9M | $15.0M |
| Free Cash FlowOCF − Capex | $124.0M | $12.8M |
| FCF MarginFCF / Revenue | 140.6% | 13.8% |
| Capex IntensityCapex / Revenue | 7.8% | 2.4% |
| Cash ConversionOCF / Net Profit | 5.53× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $207.9M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.9M | $15.0M | ||
| Q3 25 | $33.0M | $22.1M | ||
| Q2 25 | $7.7M | $8.2M | ||
| Q1 25 | $47.9M | $6.6M | ||
| Q4 24 | $124.4M | $22.2M | ||
| Q3 24 | $33.1M | $10.2M | ||
| Q2 24 | $24.0M | $18.5M | ||
| Q1 24 | $29.0M | $7.2M |
| Q4 25 | $124.0M | $12.8M | ||
| Q3 25 | $31.9M | $19.5M | ||
| Q2 25 | $6.0M | $81.0K | ||
| Q1 25 | $46.0M | $-7.6M | ||
| Q4 24 | $119.5M | $8.5M | ||
| Q3 24 | $32.0M | $-9.2M | ||
| Q2 24 | $22.9M | $1.8M | ||
| Q1 24 | $27.6M | $-6.8M |
| Q4 25 | 140.6% | 13.8% | ||
| Q3 25 | 35.8% | 28.8% | ||
| Q2 25 | 6.8% | 0.1% | ||
| Q1 25 | 54.5% | -14.5% | ||
| Q4 24 | 140.0% | 11.2% | ||
| Q3 24 | 39.7% | -15.9% | ||
| Q2 24 | 28.9% | 3.4% | ||
| Q1 24 | 34.5% | -13.3% |
| Q4 25 | 7.8% | 2.4% | ||
| Q3 25 | 1.2% | 3.9% | ||
| Q2 25 | 2.0% | 12.9% | ||
| Q1 25 | 2.3% | 27.0% | ||
| Q4 24 | 5.8% | 18.3% | ||
| Q3 24 | 1.4% | 33.5% | ||
| Q2 24 | 1.4% | 31.8% | ||
| Q1 24 | 1.9% | 27.3% |
| Q4 25 | 5.53× | 0.65× | ||
| Q3 25 | 1.47× | 4.35× | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | 6.49× | 1.12× | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMBH
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
